Informations générales (source: ClinicalTrials.gov)
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Interventional
Phase 2
IDEAYA Biosciences (Voir sur ClinicalTrials)
juillet 2023
janvier 2029
13 novembre 2024
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/12/2024 12:44:11 | Contacter | |||
Critères
Tous
Inclusion Criteria:
- Primary localized uveal melanoma requiring either enucleation or plaque
brachytherapy
- Able to dose orally
- ECOG Performance status of 0-1
- No other significant underlying ocular disease
- Adequate organ function
- Not pregnant/nursing or planning to become pregnant. Willing to use birth control
- Primary localized uveal melanoma requiring either enucleation or plaque
brachytherapy
- Able to dose orally
- ECOG Performance status of 0-1
- No other significant underlying ocular disease
- Adequate organ function
- Not pregnant/nursing or planning to become pregnant. Willing to use birth control
- Previous treatment with a Protein Kinase C (PKC) inhibitor
- Concurrent malignant disease
- Active HIV infection or Hep B/C
- Malabsorption disorder
- Unable to discontinue prohibited medication
- Impaired cardiac function or clinically significant cardiac disease
- Any other condition which may interfere with study interpretation or results